Abstract
The attempts to increase novel drug productivity through creative discovery technologies have fallen short of producing the satisfactory results. For these reasons, evolved from the concept of drug repositioning, “privileged structure”-guided scaffold re-evolution/refining is a primary strategy to identify structurally novel chemotypes by modifying the central core structure and the side-chain of the existing active compounds, or to exploit undescribed bioactivites by making full use of readily derivatized motifs with well-established synthetic protocols. Herein, we review the basic tricks of exploiting privileged structures for scaffold re-evolution/refining. The power of this strategy is exemplified in the discovery of other new therapeutic applications by refining privileged structures in anti-viral agents.
Keywords: Drug design, drug repositioning, privileged structure, scaffold re-evolution, scaffold refining.
Combinatorial Chemistry & High Throughput Screening
Title:"Old Friends in New Guise": Exploiting Privileged Structures for Scaffold Re-Evolution/Refining
Volume: 17 Issue: 6
Author(s): Yu'ning Song, Wenmin Chen, Dongwei Kang, Qingzhu Zhang, Peng Zhan and Xinyong Liu
Affiliation:
Keywords: Drug design, drug repositioning, privileged structure, scaffold re-evolution, scaffold refining.
Abstract: The attempts to increase novel drug productivity through creative discovery technologies have fallen short of producing the satisfactory results. For these reasons, evolved from the concept of drug repositioning, “privileged structure”-guided scaffold re-evolution/refining is a primary strategy to identify structurally novel chemotypes by modifying the central core structure and the side-chain of the existing active compounds, or to exploit undescribed bioactivites by making full use of readily derivatized motifs with well-established synthetic protocols. Herein, we review the basic tricks of exploiting privileged structures for scaffold re-evolution/refining. The power of this strategy is exemplified in the discovery of other new therapeutic applications by refining privileged structures in anti-viral agents.
Export Options
About this article
Cite this article as:
Song Yu'ning, Chen Wenmin, Kang Dongwei, Zhang Qingzhu, Zhan Peng and Liu Xinyong, "Old Friends in New Guise": Exploiting Privileged Structures for Scaffold Re-Evolution/Refining, Combinatorial Chemistry & High Throughput Screening 2014; 17 (6) . https://dx.doi.org/10.2174/1386207317666140122101631
DOI https://dx.doi.org/10.2174/1386207317666140122101631 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Therapeutic Exploitation of Apoptosis and Autophagy for Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Peptides in Melanoma Therapy
Current Pharmaceutical Design TRAIL: A Sword for Killing Tumors
Current Medicinal Chemistry VDAC1 as a Player in Mitochondria-Mediated Apoptosis and Target for Modulating Apoptosis
Current Medicinal Chemistry Fatty Acids - Induced Lipotoxicity and Inflammation
Current Drug Metabolism Drugs, Trials and Pathogenesis: Will Connecting these Help us Understand SLE?
Current Rheumatology Reviews The Coordinated Role of CYP450 Enzymes and P-gp in Determining Cancer Resistance to Chemotherapy
Current Drug Metabolism HIV Vaccine and Immunotherapy Approaches
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Hybrid Molecules Development: A Versatile Landscape for the Control of Antifungal Drug Resistance: A Review
Mini-Reviews in Medicinal Chemistry Radiolabeled Oligonucleotides for Antisense Imaging
Current Organic Synthesis Molecular Pharmacology of Malignant Pleural Mesothelioma: Challenges and Perspectives From Preclinical and Clinical Studies
Current Drug Targets Connecting Parkinsons Disease and Drug Addiction: Common Players Reveal Unexpected Disease Connections and Novel Therapeutic Approaches
Current Pharmaceutical Design Optimization of the Enzymolysis Conditions for Scorpion Peptides and Evaluation of its Antitumor Activity
Current Signal Transduction Therapy Discovery and Development of Natural Products and their Derivatives as Photosensitizers for Photodynamic Therapy
Current Medicinal Chemistry Current and Future Challenges in Primary Sjogren’s Syndrome
Current Pharmaceutical Biotechnology Azidothymidine is Effective Against Human Multiple Myeloma: A New Use for an Old Drug?
Anti-Cancer Agents in Medicinal Chemistry Role of Drug Metabolism in the Cytotoxicity and Clinical Efficacy of Anthracyclines
Current Drug Metabolism Dimethyloxallyl Glycine-Incorporated Borosilicate Bioactive Glass Scaffolds for Improving Angiogenesis and Osteogenesis in Critical-Sized Calvarial Defects
Current Drug Delivery Aminophosphonate Metal Complexes of Biomedical Potential
Current Medicinal Chemistry Statins and Cancer
Anti-Cancer Agents in Medicinal Chemistry